late-stage assessment Draft guidance Health technology evaluation 21 January 2025 Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over ...

In 2024, the Rx IP Update team at Smart & Biggar reported on a number of developments in Canadian life sciences IP and ...

There’s no news yet on its US list price. Along with other S1P drugs, it will also have to compete with Merck KGaA’s Mavenclad (cladribine), which has a difference mechanism of action but was ...

Those two drugs are billed as Merck 'wave 2' medicines, building on a first wave of recent launches, including PD-1 inhibitor Bavencio (avelumab), Mavenclad (cladribine) for MS and lung cancer ...